Busse R, Fleming I
Institut für Kardiovaskuläre Physiologie, Klinikum der J. W. Goethe-Universität, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.
Curr Hypertens Rep. 1999 Feb-Mar;1(1):88-95. doi: 10.1007/s11906-999-0078-6.
In normotension the endothelium produces mainly nitric oxide (NO) and prostacyclin, and the vasodilator and growth inhibitory influence predominates. Hypertension, however, is associated with a shift towards enhanced constriction and vascular hypertrophy. These effects are associated with an apparent decrease in the production of bioactive NO and concomitant increase in the generation of oxygen-derived free radicals, such as superoxide anions (O(2)-). While the enzymatic source of endothelial O(2)- has been debated intensely over the past few years, it may well turn out that the endothelial NO synthase is itself an important producer of O(2)-. Because the redox state of endothelial cells and, for example, the activation of redox-sensitive transcription factors is regulated by the balance between NO and O(2)- production, endothelial NO synthase may well be the most crucial enzyme determining the anti- or prohypertensive and eventually proatherogenic state of the vascular wall.
在血压正常时,内皮主要产生一氧化氮(NO)和前列环素,血管舒张和生长抑制作用占主导。然而,高血压与血管收缩增强和血管肥厚的转变有关。这些效应与生物活性NO生成明显减少以及氧衍生自由基如超氧阴离子(O(2)-)生成增加有关。虽然过去几年关于内皮O(2)-的酶源一直存在激烈争论,但很可能内皮型一氧化氮合酶本身就是O(2)-的重要产生者。由于内皮细胞的氧化还原状态以及例如氧化还原敏感转录因子的激活受NO和O(2)-生成之间平衡的调节,内皮型一氧化氮合酶很可能是决定血管壁抗高血压或促高血压并最终促动脉粥样硬化状态的最关键酶。